LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
14.01
-0.21 (-1.48%)
At close: Feb 9, 2026, 4:00 PM EST
14.29
+0.28 (2.00%)
After-hours: Feb 9, 2026, 5:25 PM EST
LENZ Therapeutics Revenue
LENZ Therapeutics had revenue of $12.50M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $17.50M.
Revenue (ttm)
$17.50M
Revenue Growth
n/a
P/S Ratio
22.35
Revenue / Employee
$1,590,909
Employees
11
Market Cap
438.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 15.00M | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLENZ News
- 10 days ago - New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug - Benzinga
- 26 days ago - LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign - GlobeNewsWire
- 4 weeks ago - LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates - GlobeNewsWire
- 5 weeks ago - LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East - GlobeNewsWire
- 7 weeks ago - LENZ Therapeutics: Was That A Market Overreaction? - Seeking Alpha
- 2 months ago - LENZ Therapeutics, Inc. (LENZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 months ago - LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia - GlobeNewsWire
- 2 months ago - LENZ Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire